写在文章前的声明：在本文之前的说明：本文中所列的投资信息，只是一个对基金资产净值进行排行的客观描述，并无主观倾向性，也不是投资建议，纯属 娱乐性质。 一顿操作猛如虎，基金净值已更新，谁是基金中的王者，谁又垫底，请看数据： | 基金简称 PK | | | 最新净在线 手段时间原因人 | | | --- | --- | --- | --- | --- | | 1 | 华银健康生 ... 置 | 1.3730 | 6.77% | 8 | | | 001056 | 2026-1-6 | | | | 2 | 金鹰周期优 ... A | 0.8175 | 6.56% | 8 | | | 004211 | 2026-1-6 | | | | 3 | 金鹰周期优 ... C | 0.8063 | 6.55% | 8 | | | 019748 | 2026-1-6 | | | | 4 | 东财景气驱 ... C | 1.6351 | 6.35% | | | | 019144 | 2026-1-6 | | | | 5 | 东财景气驱...A | 1.6549 | 6.35% | | | | 019143 | 2026-1-6 | ...

证券之星消息，截至2026年1月6日收盘，开立医疗(300633)报收于27.6元，上涨0.0%，换手率1.23%， 成交量5.31万手，成交额1.46亿元。 1月6日的资金流向数据方面，主力资金净流出926.33万元，占总成交额6.33%，游资资金净流出551.1万 元，占总成交额3.77%，散户资金净流入1477.43万元，占总成交额10.1%。 近5日资金流向一览见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.3 ...

开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为 39.71。 证券之星消息，截至2026年1月5日收盘，开立医疗(300633)报收于27.6元，上涨4.47%，换手率1.62%， 成交量7.03万手，成交额1.92亿元。 1月5日的资金流向数据方面，主力资金净流入1235.31万元，占总成交额6.44%，游资资金净流出 1338.34万元，占总成交额6.97%，散户资金净流入103.03万元，占总成交额 ...

Group 1: Pharmaceutical and Biotech Industry - The pharmaceutical and biotech industry in China is entering a new era of innovative drugs, transitioning from a generics-dominated market (pre-2018) to a focus on innovation from 2026 onwards, with significant growth expected in innovative drug development and commercialization [5] - The report highlights the importance of monitoring the launch rhythm of innovative drugs, competitive landscape, and key clinical data in 2026, as well as the impact of international business development (BD) transactions on cash flow [5] - The CXO and upstream scientific reagent sectors are expected to benefit from the rapid development of innovative drugs, maintaining a strong growth momentum [5] Group 2: Medical Device Industry - The medical device industry has faced significant challenges over the past three years, including anti-corruption measures and price reductions, leading to a decline in profitability for listed companies [6] - However, since 2025, there has been a gradual recovery in the industry, with improved profitability expected in 2026 as negative factors clear and new technologies like brain-computer interfaces and AI products emerge [6] - The overseas market is anticipated to become a new growth point due to companies' investments in capacity, channels, and branding [6] Group 3: Medical Services Consumption - The medical services consumption sector has been under pressure from macroeconomic conditions and policy changes, but is expected to recover as domestic consumption gradually improves [7] - The report emphasizes the potential for specialized hospitals with brand and chain advantages to lead growth in 2026, alongside the retail service market benefiting from the diversification of services [7] - A list of recommended stocks includes companies like Kelun Pharmaceutical, Rongchang Bio, and Yifeng Pharmacy, which are positioned to capitalize on these trends [7] Group 4: Manufacturing PMI Insights - The manufacturing PMI for December 2025 was reported at 50.1%, indicating a recovery from the previous value of 49.2%, driven by improved demand and supply conditions [10][11] - Factors contributing to this increase include positive expectations from recent important meetings, a recovery in trade relations, and increased pre-holiday inventory demands [10][12] - High-tech manufacturing sectors showed significant growth, with the high-tech PMI reaching 52.5%, indicating strong performance in this segment [13] Group 5: Economic Policy and Market Outlook - The central economic work conference has set a positive tone for 2026, emphasizing the importance of domestic demand and investment stabilization [15] - The report suggests that upcoming policies will focus on enhancing consumer spending and investment, with potential adjustments in housing policies expected to support the market [15] - The market is advised to focus on sectors benefiting from technological advancements and domestic consumption trends, particularly in light of anticipated policy support [16]

Core Viewpoint - The article emphasizes the importance of the IPO stage for medical device companies, highlighting that these companies often feel hesitant to communicate during this critical period [2]. Summary by Sections IPO Documentation and Communication - The article discusses the contents of the prospectus and the information that can be interpreted and utilized, as well as the communication limitations for companies before and after going public [3]. - It raises questions about the roles of marketing and branding departments during this phase, indicating a lack of systematic guidance and reliance on experiences from investment banks and listing teams [3]. Event Information - An organized event for a small group of participants is scheduled for January 15, 2026, in Shanghai, focusing on IPO-related discussions for medical device companies [4]. - The event is free but requires registration, which will be reviewed [4]. Agenda and Participants - The agenda includes self-introductions, a presentation by a guest speaker, and open discussions, targeting market/brand leaders from companies planning or undergoing IPOs, as well as management and strategic personnel [6]. - The guest speaker will cover three main topics: the readability of medical device prospectuses, compliance boundaries for communication before and after IPO, and executable promotional strategies for companies [7]. Key Topics of Discussion - The article outlines the basic structure and key modules of a prospectus, what different roles (marketing, investment, partners) typically focus on, and the distinction between factual statements and potentially misused content [7]. - It also addresses what can be communicated and what should be avoided, along with common pitfalls in promotional activities [7]. - The differences in risks before and after the IPO stage are highlighted, along with recommendations for effective communication strategies during the IPO process [7].

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

# 一个规模巨 大 、但变化缓慢的器械赛道 透析是终末期肾病患者不可替代的长期治疗方式，也是医疗器械领域中规模最大的单一治疗场景之一。但 与其市场体量并不匹配的是，该领域在治疗模式和系统效率上的变化相对有限。 在国内，透析治疗仍高度依赖中心化医疗机构，患者需长期、高频往返医院完成治疗。这一模式在保障安 全性的同时，也带来了明显的现实问题：患者时间与体力负担沉重，基层地区可及性不足，医疗机构在医 保控费和耗材集采背景下面临持续运营压力。 在此基础上，透析治疗对患者生存质量的改善空间也相对有限，使得这一领域逐渐呈现出 "刚需、高频、但 系统效率偏低" 的特征。 近日， 上海心光生物医药有限责任公司 （以下简称"心光生物"）宣布完成 数千万元A1轮融资 。本轮融资 由国际知名机构领投，老股东 兴富资本 跟投，凯乘资本担任长期财务顾问。公司表示，募集资金将主要用 于再生型腹膜透析产品的型式检验、临床试验及注册申报等关键节点。 在当前医疗器械投资更加关注 "是否解决真实系统性问题" 的背景下，心光生物所切入的透析赛道，并非高 速变化的热门领域，却长期存在结构性矛盾。本轮融资，更多体现的是资本对透析治疗模式调整可能性的 ...

Core Viewpoint - The company, Shenzhen Kaili Biomedical Technology Co., Ltd., has undergone significant governance changes, including the cancellation of its supervisory board and amendments to its articles of association, which were approved during its recent shareholder meeting [2][4]. Group 1: Stock Performance - As of December 31, 2025, the stock price of Kaili Medical closed at 26.42 yuan, down 0.49% from the previous week [1]. - The stock reached a high of 26.59 yuan and a low of 25.92 yuan during the week [1]. - The company's current total market capitalization is 11.432 billion yuan, ranking 26th out of 127 in the medical device sector and 1709th out of 5181 in the A-share market [1]. Group 2: Corporate Governance Changes - The second extraordinary general meeting of shareholders was held on December 30, 2025, where the cancellation of the supervisory board and amendments to the company's governance structure were approved [2][4]. - The meeting was deemed legal and effective, with 55.3717% of the total voting rights represented by attending shareholders [2][4]. - The proposals to cancel the supervisory board and amend the articles of association received over two-thirds approval, while other proposals received a majority [2]. Group 3: Employee Representation - The company held a representative assembly on December 30, 2025, electing Feng Naizhang as the employee representative director for the fourth board of directors [3]. - Feng Naizhang, previously a non-employee representative director, meets the qualifications set forth in the Company Law and the company's articles of association [3]. - The composition of the board and its specialized committees remains unchanged, with the number of concurrent executives and employee representative directors not exceeding half of the total board members [3].

Core Viewpoint - The medical device sector is becoming one of the most certain and continuously evolving segments within the healthcare system, with ten related markets entering an acceleration phase due to clinical demand, payment logic, and technological maturity [2]. Summary by Relevant Sections Accelerating Medical Device Markets - Ten medical device markets are identified as entering an acceleration phase, indicating a significant shift in how medical services are provided, executed, and managed [2][3]. Market Growth Projections - **Disposable Endoscopes Market**: Expected to grow from $840 million in 2024 to $2.67 billion by 2030, with a CAGR of 22.9% [5]. - **Dental 3D Printing Market**: Projected to increase from $3.4 billion in 2024 to $10.06 billion by 2030, with a CAGR of 20.5% [6]. - **Surgical Imaging Market**: Anticipated to rise from $3.9 billion in 2023 to $12.2 billion by 2030, with a CAGR of 17.6% [7]. - **Surgical Robots Market**: Expected to grow from $9.6 billion in 2023 to $23.7 billion by 2029, with a CAGR of 16.5% [8]. - **Medical Robots Market**: Projected to increase from $13.8 billion in 2023 to $33.8 billion by 2029, with a CAGR of 16.1% [9]. - **Minimally Invasive Surgery Market**: Expected to grow from $81.65 billion in 2024 to $199.3 billion by 2030, with a CAGR of 16.1% [10]. - **Surgical Instrument Tracking System Market**: Anticipated to rise from $31.4 million in 2024 to $75.1 million by 2030, with a CAGR of 15.2% [12]. - **Autoinjectors Market**: Expected to grow from $1.08 billion in 2024 to $3.02 billion by 2030, with a CAGR of 13.6% [14]. - **Medical Aesthetics Market**: Projected to increase from $17.16 billion in 2024 to $35.32 billion by 2030, with a CAGR of 12.8% [15]. - **Diabetes Care Devices Market**: Expected to grow from $34.3 billion in 2025 to $61.2 billion by 2030, with a CAGR of 12.3% [16]. Common Directions Behind Growth - The ten markets are not isolated; they point towards several clear trends: - Medical services are becoming "de-experienced," with devices taking over tasks previously reliant on personal experience to reduce uncertainty [18]. - Efficiency is becoming a critical consideration in payment and procurement, driving growth in imaging, tracking, and disposable products [19]. - Minimally invasive and low-invasion procedures are becoming the default assumption rather than an optional choice [19]. - Healthcare is transitioning from "single-point devices" to "systematic operations," with platform, modular, and process capabilities becoming the new core of competition [20]. Reasons for Current Acceleration - The changes are not sudden but are the result of the convergence of technological maturity, shifts in payment logic, and structural labor shortages in healthcare, leading to a focus on devices that can change operational methods [21].

Core Viewpoint - The financial performance of Kaili Medical (300633) shows mixed results, with a slight increase in revenue but a significant decline in net profit, indicating potential challenges ahead for the company [2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of December 31, 2025, Kaili Medical's stock closed at 26.42 yuan, up 0.84%, with a turnover rate of 0.92% and a trading volume of 40,000 hands, amounting to a transaction value of 105 million yuan [1]. - On December 31, the net inflow of main funds was 15.99 million yuan, accounting for 15.25% of the total transaction value, while retail funds saw a net outflow of 5.25 million yuan, representing 5.01% of the total transaction value [1]. Analyst Ratings - In the last 90 days, 11 institutions have provided ratings for Kaili Medical, with 9 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 3.971 billion yuan [2].